Bioseeker, Feb 2011
. In addition, there are 6 (2) suspended drugs and the accumulated number of ceased drugs over the last years amount to another 291 (285) drugs. Antibodies In OncologyDrugPipelineUpdate lists all drugs
La Merie, Dec 2011, Pages: 70
projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor
Bioseeker, Sep 2011
in Cancer: The Faster Route to Consider Your Options and Position of Others
Antibodies in Oncology: DrugPipelineUpdate 2011-
The Package Includes
- A progress analysis on current and emerging drugs
Bioseeker, Nov 2011
and Position of Others
Antibodies in OncologyDrugPipelineUpdate 2011-
Peptides in OncologyDrugPipelineUpdate 2011-
The Package Includes:
- A progress analysis on current and emerging drugs
La Merie, Feb 2011, Pages: 183
validity. The technology of antibody-drug conjugates is gaining popularity as evidenced by an ever growing pipeline.
The report includes a compilation of currently active projects in early clinical
La Merie, Feb 2012
Subscription to the AntibodyPipeline Database provides online access to more than 1,600 project entries for therapeutic antibodies on the market and in research & development. Each project
La Merie, Feb 2012
Subscription "OncologyPipeline Database" provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category
Bioseeker, Dec 2007, Pages: 430
OncologyAntibodyDrug Targets
Table 2: Cancer AntibodyPipeline Listed by Carboxypeptidase Activity Targets
Table 3: Cancer AntibodyPipeline Listed by Catalytic Activity Targets
Table 4: Cancer Antibody
Bioseeker, Feb 2011
? Cancer Vaccines: Aim and Shoot Immunotherapy in OncologyDrugPipelineUpdate 2011- The Package Includes A progress analysis on current and emerging drugs Information on most companies active
Bioseeker, June 2006 Antibodies - The Formation of a Second Wave and Antibodies in Oncology: DrugPipelineUpdate 2007-.
The Package Includes
A progress analysis on current and emerging drugs
Information on most oncology
GlobalData, Nov 2010, Pages: 20
of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the 4-Antibody AG’s pipeline in the last quarter.
- Key discontinued and dormant
Global Markets Direct, Nov 2010, Pages: 20
of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the 4-Antibody AG’s pipeline in the last quarter.
- Key discontinued and dormant
La Merie, Feb 2012
of the subscription provides a 1-year online access to the data of the AntibodyPipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the Antibody
Bioseeker, Feb 2011
In OncologyDrugPipelineUpdate lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 336 (315) different targets. These targets are further categorized
Bioseeker, Feb 2011
This drugpipelineupdate covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies.
There are today 675 companies plus partners developing
Bioseeker, Feb 2011
This drugpipelineupdate covers proteins, excluding antibodies, as drugs for the treatment of cancer.
There are today 311 companies plus partners developing 338 protein drugs in 571 developmental
Spectra Intelligence, Oct 2009, Pages: 81
, will introduce the reader a specialty pharmaceutical market which is positioned for high-growth based on analysis of marketed and pipelinedrugs, company activities, and addiction disorder demographics.
Therapy
GBI Research, Dec 2010, Pages: 198
of clinical need that are unmanageable with conventional therapeutics, such as oncology, infectious diseases including HIV, and autoimmune disorders. A strong product pipeline for most of the top 10
Bioseeker, Sep 2007, Pages: 500
by Cancer Indications
7.3 Deployment of Natural Product Compounds by Cancer Indications
8 Drug Development in Oncology by Major Targeted Therapy Areas
8.1 Angiogenesis
8.2 Antibodies
8.3 Apoptosis
8
